Why the study?
Does Fcγ-receptor IIa polymorphism influence the efficacy of immunoadsorption therapy in improving LV function in patients with dilated cardiomyopathy?
Does Fcγ-receptor IIa polymorphism influence the efficacy of immunoadsorption therapy in improving LV function in patients with dilated cardiomyopathy?
The Fcγ-receptor IIa R/R131 genotype is associated with a greater improvement in left ventricular function following immunoadsorption therapy in patients with dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
R/R131 genotype associated with greater LV recovery after immunoadsorption in dilated cardiomyopathy; hypothesis-generating and needs prospective validation before guiding therapy.
Staudt et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: